GB899011A - Rubeola vaccine and process - Google Patents

Rubeola vaccine and process

Info

Publication number
GB899011A
GB899011A GB5115/59A GB511559A GB899011A GB 899011 A GB899011 A GB 899011A GB 5115/59 A GB5115/59 A GB 5115/59A GB 511559 A GB511559 A GB 511559A GB 899011 A GB899011 A GB 899011A
Authority
GB
United Kingdom
Prior art keywords
virus
medium
rays
preferred
cultures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5115/59A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB899011A publication Critical patent/GB899011A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165Mumps or measles virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18451Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A rubeola (measles) virus vaccine is produced by growing measles virus on monkey (i.e. any primate except man or lemurs) renal cell cultures, harvesting the live virus therefrom in a parenterally acceptable vehicle and destroying the infective capacity of the virus. The preferred cell culture is that of renal cells from African vervet monkeys (Cercopithecus lalandi). Those from rhesus, cynomolgus and squirrel monkeys and those of simians, e.g. chimpanzee and baboons, may be used if substantially free from competitive latent viruses. Propogation is by any well known tissue culture technique, e.g. Maitland minced tissue method, submerged culture of suspended cells or cultures of cells grown on glass (preferred). Any complete tissue culture nutrient medium may be used, e.g. "medium 199," Eagles medium, medium NCTC 107 which may advantageously include about 5% to 10% of a filtered mamalian serum, e.g. calf serum (preferred). The medium may also contain agents to prevent bacterial or mycotic growth, e.g. penicillin, streptomycin, mycostatin, parabens. The cultures are incubated at about 25 DEG to 40 DEG C. (preferably 32 DEG to 38 DEG C.) for about 5 to 12 days and the virus is then harvested in a parenterally acceptable medium, e.g. those mentioned above, one of, these being used to replace the growth medium if unsuitable (e.g. contains mammalian serum). Cellular debris is removed by centrifugation and the virus is inactivated by conventional means, e.g. by chemicals, e.g. formaldehyde, b -propiolactone, mustard oils or chlorine or by forms of physical energy, e.g. heat (45 DEG C. for 30 hours or 25 DEG C. for 200 hours), ultra-violet radiation, ionizing radiations (preferred), e.g. a -rays, cathode-rays, b -rays, g -rays or protons, the virus being present in variable conditions, e.g. in liquid or frozen suspensions, as a lyophilised powder in bulk or in sealed containers, e.g. of glass or low density polythene. Preservatives, e.g. benzethenium chloride, parabens or "Merthiolate" (Registered Trade Mark) may be added to the final vaccine.
GB5115/59A 1958-03-14 1959-02-13 Rubeola vaccine and process Expired GB899011A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72136458A 1958-03-14 1958-03-14

Publications (1)

Publication Number Publication Date
GB899011A true GB899011A (en) 1962-06-20

Family

ID=24897679

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5115/59A Expired GB899011A (en) 1958-03-14 1959-02-13 Rubeola vaccine and process

Country Status (1)

Country Link
GB (1) GB899011A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3186908A (en) * 1962-08-16 1965-06-01 Parke Davis & Co Calcium lactobionate stabilization of labile antigenic virus vaccine materials
WO2015011265A1 (en) * 2013-07-26 2015-01-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for inactivating viruses using electron beams

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3186908A (en) * 1962-08-16 1965-06-01 Parke Davis & Co Calcium lactobionate stabilization of labile antigenic virus vaccine materials
WO2015011265A1 (en) * 2013-07-26 2015-01-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for inactivating viruses using electron beams
CN105431171A (en) * 2013-07-26 2016-03-23 弗劳恩霍弗促进应用研究注册公司 Method for inactivating viruses using electron beams
US10080795B2 (en) 2013-07-26 2018-09-25 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for inactivating viruses using electron beams
US10881724B2 (en) 2013-07-26 2021-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for inactivating viruses using electron beams

Similar Documents

Publication Publication Date Title
Rowe et al. Characterization of a factor formed in the course of adenovirus infection of tissue cultures causing detachment of cells from glass
RU94046296A (en) METHODS FOR PRODUCING A VACCINE, METHOD OF CULTIVATION OF CELLS, COMPOSITION
Epstein et al. Histocompatibility typing and course of canine venereal tumors transplanted into unmodified random dogs
Sykes et al. Observations on a cell line producing mammary tumor virus
Lee et al. Human astrovirus serotypes
Baron et al. New maintenance medium for cell culture
Fahmy et al. Mutagenicity of 2-chloroethyl methanesulphonate in Drosophila melanogaster
GB899011A (en) Rubeola vaccine and process
Gravell et al. Viruses and renal carcinoma of Rana pipiens: IX. The influence of temperature and host cell on replication of frog polyhedral cytoplasmic deoxyribovirus (PCDV)
US4169761A (en) Process for the cultivation of viruses
Melnick et al. Stabilized Suspensions of Monkey Kidney Cells Suitable for Intercontinental Shipment.
Hollaender et al. X. Modification of Radiation Damage After Exposure to X Rays
Harvey Note on the Absorption of Organic Phosphorus Compounds by NitzschiaClosterium in the Dark
Band Biotin, a growth requirement for four soil amoebae
Shimura et al. Extracellular release of photosynthetic products by a pelagic blue-green alga, Trichodesmium thiebautii
GB1492930A (en) Virus growth
ATE322540T1 (en) PREPARATION FOR TRANSFER OF ACTIVE TUMOR-SPECIFIC IMMUNIZATION FROM AN IMMUNIZED ALLOGENEIC BONE MARROW DONOR
CN110305792A (en) A method of the separation micro- frosting microorganism of soil
Goldner et al. Immunity against a transplantable ascites tumor of spontaneous origin in an inbred rat strain
Lapin Epidemiology of leukemia among baboons of Sukhumi monkey colony
Gibbs et al. Preliminary experiments to determine which host ribosomes are used by some further plant viruses
Mefferd Jr et al. Influence of temperature upon radiation sensitivity of thermophilic and mesophilic bacteria
Buchner et al. Infectious hepatitis and the cytological response in embryonated eggs
US3629470A (en) Process for purification of animal rna viruses
Heath A constitutive enzyme system for glucose transport by Chlorella sorokiniana